Advertisement
UK markets open in 7 hours 3 minutes
  • NIKKEI 225

    38,405.66
    +470.90 (+1.24%)
     
  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     
  • CRUDE OIL

    81.32
    -0.61 (-0.74%)
     
  • GOLD FUTURES

    2,303.10
    +0.20 (+0.01%)
     
  • DOW

    37,815.92
    -570.17 (-1.49%)
     
  • Bitcoin GBP

    48,629.01
    -2,479.00 (-4.85%)
     
  • CMC Crypto 200

    1,297.73
    -41.34 (-3.09%)
     
  • NASDAQ Composite

    15,657.82
    -325.26 (-2.04%)
     
  • UK FTSE All Share

    4,430.25
    -4.93 (-0.11%)
     

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction. According to a recent SEC filing, CEO Stephen Davis sold 26,574 shares of the company on April 8, 2024.The transaction history of the insider over the past year indicates that Stephen Davis has sold a total of 284,568 shares and has not made any purchases of the company's stock.The insider trends for ACADIA Pharmaceuticals Inc show a pattern of insider selling, with 34 insider sells and only 1 insider buy over the past year.

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares

On the valuation front, shares of ACADIA Pharmaceuticals Inc were trading at $17.87 on the day of the insider's recent sell, giving the company a market capitalization of $2.993 billion.The stock's price-to-GF-Value ratio stands at 0.56, with a GuruFocus Value of $32.03, indicating that ACADIA Pharmaceuticals Inc is significantly undervalued based on its GF Value.

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares

The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.

ADVERTISEMENT

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.